New Depression Treatments in 2026

By the clinical team at Next Step Psychiatry • Lilburn, GA

A New Era for Depression Treatment

If you’ve struggled with depression and felt like the available treatments haven’t worked, 2026 offers reasons for optimism. The landscape of depression treatment is undergoing its most significant transformation in decades, with new medications, devices, and therapeutic approaches reaching patients for the first time. From at-home brain stimulation to single-dose psychedelic treatments, the options are expanding rapidly.

Here’s what’s new, what’s coming, and what it means for patients in Georgia.

Gepirone: A Gentler Antidepressant with Fewer Side Effects

Gepirone ER (marketed as Exxua) represents a different approach to treating depression. It’s a selective 5-HT1A receptor agonist—meaning it targets a specific serotonin receptor rather than flooding the brain with serotonin like SSRIs do. The result? Effective antidepressant action with significantly lower rates of sexual dysfunction, weight gain, and emotional blunting.

For patients who’ve avoided or abandoned antidepressants due to side effects, gepirone could be a welcome alternative. It’s particularly promising for patients who value their sexual health and want an antidepressant that doesn’t compromise it.

At-Home Brain Stimulation: FDA-Approved in Late 2025

In December 2025, the FDA approved the first at-home, prescription brain stimulation device for adults with treatment-resistant major depression. The Flow Neuroscience headset uses transcranial direct current stimulation (tDCS) to modulate neural activity in the prefrontal cortex—the brain region most affected by depression.

Patients wear the device for 30 minutes during regular activities. Early results show meaningful improvement in depressive symptoms with minimal side effects (mild tingling at the electrode site). ProlivRx, another at-home brain neuromodulation device, received FDA approval for MDD patients who failed antidepressants, with availability expected in early 2026.

Zuranolone: A Rapid-Acting Pill for Depression

Zuranolone (Zurzuvae) made headlines as the first oral medication specifically designed for rapid treatment of postpartum depression. Unlike traditional antidepressants that take weeks, zuranolone can produce noticeable improvement within days. It works by modulating GABA-A receptors, a completely different mechanism from SSRIs.

The 14-day treatment course is particularly appealing—rather than indefinite daily medication, patients take zuranolone for two weeks and may experience sustained benefits. Research is ongoing for its use in major depressive disorder beyond postpartum depression.

Spravato Monotherapy and Beyond

The expanded approval of Spravato (esketamine) as a standalone treatment for treatment-resistant depression was one of the biggest developments of 2025. Previously requiring combination with an oral antidepressant, Spravato can now be the sole medication for appropriate patients. At Next Step Psychiatry, we’re a REMS-certified Spravato center and have seen remarkable results.

Looking ahead, psilocybin-assisted therapy for depression continues advancing through clinical trials, with several Phase 3 studies underway. While not yet FDA-approved, the data is compelling enough that it could reach patients within the next few years.

Access to New Treatments in Georgia

At Next Step Psychiatry, we’re committed to bringing the latest evidence-based treatments to our patients in Lilburn, Gwinnett County, and across Georgia. We were early adopters of Spravato and continually evaluate emerging treatments as they become available. If you’ve been struggling with depression that hasn’t responded to traditional treatments, there has never been more reason for hope.

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider. If you or someone you know is in crisis, call 911 or the 988 Suicide & Crisis Lifeline.